Last reviewed · How we verify
ActiveMatrix
ActiveMatrix is a matrix metalloproteinase inhibitor.
ActiveMatrix is a matrix metalloproteinase inhibitor. Used for Treatment of glioblastoma.
At a glance
| Generic name | ActiveMatrix |
|---|---|
| Sponsor | Baylor College of Medicine |
| Drug class | matrix metalloproteinase inhibitor |
| Target | matrix metalloproteinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
It works by inhibiting the activity of matrix metalloproteinases, enzymes involved in the breakdown of the extracellular matrix. This mechanism is thought to contribute to its therapeutic effects in various conditions.
Approved indications
- Treatment of glioblastoma
Common side effects
- Fatigue
- Nausea
- Headache
Key clinical trials
- A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder (PHASE4)
- Prospective Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft Active Matrix (AM) vs. Standard of Care in Arthroscopic Rotator Cuff Repair (NA)
- Efficacy of ActiveMatrix on Spinal SSI Rate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ActiveMatrix CI brief — competitive landscape report
- ActiveMatrix updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI